AbbVie 8-K
NegativeEarningsGuidance loweredImpairment / charge
Acquired in-process R&D and milestone expenses lower Q4 and FY2025 adjusted EPS guidance.
Filed 2026-01-07 16:08 ET
- 2.02 Results of Operations
- 9.01 Financial Statements and Exhibits
Summary
Q4 and FY2025 adjusted EPS guidance update. AbbVie included a Q4 acquired in-process research and development and milestones expense in its outlook, lowering adjusted diluted EPS guidance for both periods. Q4 results are preliminary and remain subject to financial statement closing procedures.
Key Figures
- Q4 acquired expense: $1.27B pre-tax, with an unfavorable $0.71 impact on both GAAP and adjusted diluted EPS; the expense is included in FY2025 guidance at $5.02B.
- The expense accounts for the lower adjusted EPS ranges versus the previously announced outlook, which excluded the Q4 expense.
Guidance
| Metric | Period | Guidance | Prior | Direction |
|---|---|---|---|---|
| Adjusted diluted EPS, non-GAAP | Q4 2025 | $2.61-$2.65 | $3.32-$3.36, excluding Q4 expense | Lowered |
| Adjusted diluted EPS, non-GAAP | FY2025 | $9.90-$9.94 | $10.61-$10.65, excluding Q4 expense | Lowered |
Investor Takeaways
- Final Q4 results will confirm the expense and EPS figures; AbbVie cautions that closing procedures could change the preliminary estimates.
The summary is written by an AI model reading the filing.
Model 005 · prompt 01d34d48e3